Tags: Cancer | odomza | skin | cancer | drug | basal

FDA Approves Skin Cancer Medication

Friday, 24 July 2015 03:49 PM

A new drug for advanced basal cell carcinoma, an increasingly common cancer in the skin's top layer, has won Food and Drug Administration approval.

Odomza (pronounced ah-DOMM'-zoh) was approved for patients whose cancer hasn't spread to other body parts, but recurred after surgery or radiation therapy or can't be cured by those treatments.

The drug, known chemically as sonidegib (seh-NEH'-deh-gib), is a daily pill developed by Swiss drugmaker Novartis AG, which has U.S. pharmaceuticals headquarters in East Hanover, New Jersey.

It can stop or reduce growth of cancerous lesions by suppressing a key molecular pathway. Side effects include muscle spasms and damage, hair loss, nausea, diarrhea and, in pregnant women, risk of death or birth defects in the fetus.

Novartis hasn't disclosed the drug's price, but will launch it soon.

© Copyright 2019 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

   
1Like our page
2Share
Health-News
A new drug for advanced basal cell carcinoma, an increasingly common cancer in the skin's top layer, has won Food and Drug Administration approval. Odomza (pronounced ah-DOMM'-zoh) was approved for patients whose cancer hasn't spread to other body parts, but recurred after...
odomza, skin, cancer, drug, basal
130
2015-49-24
Friday, 24 July 2015 03:49 PM
Newsmax Media, Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved